Understanding the biology of HER3 receptor as a therapeutic target in human cancer.

Lyu, Hui; Han, Amy; Polsdofer, Erik; Liu, Shuang; Liu, Bolin

Lyu, Hui; Han, Amy; Polsdofer, Erik; Liu, Shuang; Liu, Bolin.

Afiliación

Lyu H; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Han A; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Polsdofer E; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Liu S; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Liu B; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Acta Pharm Sin B ; 8(4): 503-510, 2018 Jul.

Article en En | MEDLINE | ID: mdl-30109175

Palabras clave

ADCC, antibody-dependent cell-mediated cytotoxicity; Ab, antibody; Cell signaling; Dimerization; EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; FDA, Food and Drug Administration; HER, Human epidermal growth factor receptor; HER3; HRG, heregulin; IGF-1R, insulin-like growth factor-I receptor; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; NSCLC, non-small cell lung cancer; OS, overall survival; PI-3K, phosphoinositide 3-kinase; RTK, receptor tyrosine kinase; TKI, tyrosine kinase inhibitor; Targeted therapy; Therapeutic resistance; Tumor metastasis; lncRNA, long ncRNA; miRNA, microRNA; ncRNA, noncoding RNA

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Acta Pharm Sin B Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google